Elsevier

The Lancet

Volume 340, Issue 8823, 3 October 1992, Pages 819-820
The Lancet

SHORT REPORTS
Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn

https://doi.org/10.1016/0140-6736(92)92687-BGet rights and content

Abstract

We studied the effects of inhaled nitric oxide (NO) in 9 newborn infants with severe persistent pulmonary hypertension (PPHN) who were candidates for extracorporeal membrane oxygenation treatment. With low doses of NO (10-20 ppm) all showed rapid improvement in oxygenation without reduction of systemic blood pressure. In 6 infants treated with inhaled NO for 24 h, clinical improvement was sustained at 6 ppm.

References (9)

There are more references available in the full text version of this article.

Cited by (663)

  • Utility of NO and H<inf>2</inf>S donating platforms in managing COVID-19: Rationale and promise

    2022, Nitric Oxide - Biology and Chemistry
    Citation Excerpt :

    iNO is used for the clinical management of hypoxic respiratory failure in neonates. Several studies have shown that iNO improves oxygenation, reduces pulmonary arterial pressure, and reduces the need for extracorporeal membrane oxygenation (ECMO) in newborns with persistent pulmonary hypertension [217–222]. In 1999, the FDA approved the use of iNO for treating persistent pulmonary hypertension in newborns.

  • Nitric oxide: Clinical applications in critically ill patients

    2022, Nitric Oxide - Biology and Chemistry
    Citation Excerpt :

    iNO improves oxygenation and decreases extracorporeal membrane oxygenation (ECMO) use in term and late preterm newborns with PPHN. It was Kinsella et al. [74] and Roberts et al. [75], who first described the benefit of iNO up to 80 ppm on oxygenation in newborns with PPHN. Since then, many trials confirmed these results and found a reduction in ECMO use with iNO treatment [30,38,50,74,75].

View all citing articles on Scopus
View full text